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alleviate the non-motor symptoms as well as the underlying dopaminergic neuron
degeneration. On the other hand, there is increasing evidence that inﬂammation plays a
key role in the pathophysiology of PD and that the anti-inﬂammatory actions of statins
are related to their neuroprotective properties against different insults in the CNS. The
present data indicates that the oral treatment with atorvastatin (10 mg/kg/day), once a day
during 7 consecutive days, was able to prevent short-term memory impairments and
depressive-like behavior of rats assessed in the social recognition and forced swimming
tests at 7 and 14 days, respectively, after a single intranasal (i.n.) administration of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (1 mg/nostril). Importantly, at this time
no signiﬁcant alterations on the locomotor activity of the animals were observed in the
open ﬁeld test. Moreover, atorvastatin was found to protect against the long-lasting motor
deﬁcits evaluated in activity chambers and the loss of dopaminergic neurons in the
substantia nigra pars compacta observed at 21 days after i.n. MPTP administration. At this
time, despite the absence of spatial memory deﬁcits in the water maze and in concentra-
tions of the cytokines TNF-α, IL-1β and IL-10 in striatum and hippocampus following i.n.
MPTP administration, atorvastatin treatment resulted in a signiﬁcant increase in the
striatal and hippocampal levels of nerve growth factor (NGF). These ﬁndings reinforce and
extend the notion of the neuroprotective potential of atorvastatin and suggest that it may9
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b r a i n r e s e a r c h 1 5 1 3 ( 2 0 1 3 ) 1 0 3 – 1 1 6104represent a new therapeutic tool for the management of motor and non-motor
symptoms of PD.
& 2013 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Parkinson's disease (PD) is the second more common neurode-
generative disorder affecting 1–2% of individuals older than 60
years and estimated prevalence is 5 million individuals world-
wide (De Lau and Breteler, 2006). PD is a debilitating disease
primarily characterized by the progressive loss of neuromelanin-
containing dopaminergic neurons in the substantia nigra pars
compacta (SNpc) with presence of eosinophillic, intracytoplas-
mic, proteinaceous inclusions termed as Lewy bodies and
dystrophic Lewy neurites in surviving neurons (Hirsch et al.,
1988). At the time of diagnosis, patients typically display an array
of motor impairments including bradykinesia, resting tremor,
rigidity, and postural instability. Although most of the typical
motor impairments are due to the severe loss of nigrostriatal
dopaminergic neurons, PD affects multiple neuronal systems
both centrally and peripherally, leading to a constellation of non-
motor symptoms including olfactory deﬁcits, affective disorders,
memory impairments, as well as autonomic and digestive
dysfunction (Chaudhuri and Odin, 2010). These non-motor
features of PD do not meaningfully respond to dopaminergic
medication and are a challenge to the clinical management of PD
(Chaudhuri and Odin, 2010).
To date, most studies performed with animal models of PD
have investigated their ability to induce nigrostriatal dopaminer-
gic pathway damage and motor alterations associated with
advanced phases of PD (Duty and Jenner, 2011). As current
research continues to unmask PD as a multi-system disorder,
animal models should similarly evolve to include the non-motor
features of the disease (Taylor et al., 2010). In this context, we
have recently proposed a new experimental model of PD con-
sisting of a single intranasal (i.n.) administration of the proneur-
otoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in
rodents (for review see Prediger et al., 2011). Our previous
ﬁndings demonstrate that rats (Prediger et al., 2006, 2009;
Moreira et al., 2010; Castro et al., 2012) and mice (Prediger
et al., 2010; Matheus et al., 2012) infused intranasally with MPTP
suffer impairments in olfactory, cognitive, emotional and motor
functions conceivably analogous to those observed during dif-
ferent stages of PD. Such infusion causes time-dependent loss of
tyrosine hydroxylase (TH) in the olfactory bulb and SNpc of rats,
resulting in signiﬁcant dopamine depletion in different brain
areas (Prediger et al., 2006, 2009; Moreira et al., 2010; Castro et al.,
2012). Therefore, the i.n. MPTP administration appears to be an
ecologically valid means for assessing novel neuroprotective and
palliative treatments for both the motor and non-motor
symptoms of PD.
On the other hand, there is growing recognition that neuroin-
ﬂammatory mechanisms might contribute to the cascade of
events leading to neuronal degeneration in PD (for review see
Hirsch and Hunot, 2009). Post-mortem studies revealed an
increase in activated glial cells in the substantia nigra (McGeer
et al., 1988) and in concentrations of cytokines such as tumor
necrosis factor alpha (TNF-α), and interleukin (IL)-1β, IL-2, IL-4, IL-6 in the striatum (Mogi et al., 1994; Nagatsu et al., 2000) of
patients with PD. Further studies in animal models support the
idea that neuroinﬂammation can increase neuronal degenera-
tion in PD. For instance, microglial activation and accumulation
of inﬂammatory mediators in the substantia nigra, striatum and
hippocampus have been described after MPTP injection in mice
(Liberatore et al., 1999; Sriram et al., 2002) and rats (Wang et al.,
2009, 2010). Thus, therapeutic strategies aimed at downregulat-
ing these inﬂammatory processes might be important to slow
the progression of PD.
In this context emerges statins that are competitive inhibitors
of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase, the key enzyme that regulates the biosynthesis of choles-
terol. Recently, it has been demonstrated that statins have
“pleiotropic” effects independent of cholesterol reduction that
include anti-inﬂammatory and immunomodulating effects
(Wood et al., 2010; Wang et al., 2011). There is increasing
evidence from clinical and animal studies that statins might be
beneﬁcial as a therapy for depression (Ludka et al., 2012) and
dementia (Jick et al., 2000; Wolozin et al., 2007), although the
exact mechanisms remain unclear. Several prospective studies
have been conducted to examine the association between statin
use and PD risk and have generatedmixed results (Hippisley-Cox
and Coupland, 2010; Ritz et al., 2010; Gao et al., 2012). Moreover,
recent experimental ﬁndings have demonstrated the protective
effects of statins (mainly simvastatin) against the dopaminergic
neurodegeneration induced by different PD-mimetic toxins, such
as MPTP and its active metabolite 1-methyl-phenylpyridinium
(MPP+) (Selley, 2005; Kreisler et al., 2007; Ghosh et al., 2009),
6-hydroxydopamine (6-OHDA) (Yan et al., 2011; Kumar et al.,
2012) and lipopolysaccharide (LPS) (Hernández-Romero et al.,
2008). Of high importance, previous studies using both MPTP-
and 6-OHDA-induced animal models of PD reported that statins
attenuate the production of inﬂamatory markers such as TNF-α
and IL-6, nitric oxide, and superoxide in activated microglia
thereby protecting dopaminergic neurons from inﬂammatory
damage (Selley, 2005; Yan et al., 2011; Kumar et al., 2012).
In spite of the available literature indicating the neuroprotec-
tive potential of statins in PD, no consistent evidence for the
effects of such agents in the non-motor symptoms of PD has to
date been documented. Therefore, the aim of the present study
was to evaluate the potential of the treatment with atorvastatin
to improve non-motor symptoms of PD, including short-term
memory deﬁcits and depressive-like behavior, induced by a
single i.n. MPTP administration in rats.2. Results
2.1. Social recognition
Fig. 1 shows a schematic illustration of the treatment
schedule and the time course of behavioral and biochem-
ical analysis performed in two independent cohorts rats.
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Fig. 2 – Effects of the pretreatment (during 7 consecutive
days) with saline or atorvastatin (10 mg/kg, p.o.) on the
social recognition memory of rats evaluated 7 days after i.n.
infusion of MPTP (1 mg/nostril). Data are expressed as the
mean7S.E.M. of RIDs (i.e. the ratio of the second exposure
to the first exposure) when the same juvenile was exposed
for 5 min with an interval of 30 min [control/control (n¼9);
control/MPTP (n¼11); atorvastatin/control (n¼7); and
atorvastatin/MPTP (n¼8)]. nP≤0.05 compared to the control/
control group. #P≤0.05 compared to the control/MPTP group
(two-way ANOVA followed by Newman–Keuls test).
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Fig. 1 – Schematic illustration of the time course of behavioral and neurochemical tests following the pretreatment (during 7
consecutive days) with control (saline) or atorvastatin (10 mg/kg, p.o.) and a single intranasal (i.n.) administration of control
(saline) or MPTP (1 mg/nostril) in adult male Wistar rats.
b r a i n r e s e a r c h 1 5 1 3 ( 2 0 1 3 ) 1 0 3 – 1 1 6 105The results for the effects of i.n. administration of MPTP
(1 mg/nostril) on the short-term social recognition mem-
ory of rats pretreated with saline or atorvastatin (10 mg/kg, p.o.) are illustrated in Fig. 2. Two-way ANOVA revealed
signiﬁcant effects for the pretreatment [F(1,31)¼4.63; P¼0.032],
treatment [F(1,31)¼3.68; P¼0.044] and their interaction [F
(1,31)¼8.42; P¼0.015] in the ratio of investigation duration
(RID). Post-hoc comparisons indicated that the i.n. MPTP
administration promoted a signiﬁcant increase in the RID
(P¼0.011) when the same juvenile rat was re-exposed 30min
after the ﬁrst encounter, indicating a disruption in the social
recognition ability of adult rats. Remarkably, pretreatment
with atorvastatin prevented the deﬁcit in social recognition
ability induced by i.n. MPTP administration, inducing a sig-
niﬁcant reduction in the RID (P¼0.014) when the same juvenile
was re-exposed after 30min.2.2. Open-ﬁeld
The results of locomotor activity evaluated in the open ﬁeld
arena (for 5 min) at 14 days after i.n. MPTP (1 mg/nostril)
administration are summarized in Fig. 3. Two-way ANOVA
(pretreatment versus treatment) revealed no signiﬁcant
effects for the main factors in the total distance traveled
[pretreatment: F(1,31)¼1.24, P¼0.27; treatment: F(1,31)¼0.58,
P¼0.45] (Fig. 3A) and in the average speed [pretreatment:
F(1,31)¼1.30, P¼0.26; treatment: F(1,31)¼0.59, P¼0.44] (Fig. 3B).
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Fig. 3 – Effects of the pretreatment (during 7 consecutive
days) with saline or atorvastatin (10 mg/kg, p.o.) on the
locomotor activity of rats evaluated in the open field 14 days
after i.n. infusion of MPTP (1 mg/nostril). Data are expressed
as the mean7S.E.M. of the distance traveled (A) and average
speed (B) during 5 min [control/control (n¼9); control/MPTP
(n¼11); atorvastatin/control (n¼7); and atorvastatin/MPTP
(n¼8)].
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Fig. 4 – Effects of the pretreatment (during 7 consecutive
days) with saline or atorvastatin (10 mg/kg, p.o.) on
depressive-like behavior of rats evaluated 14 days after i.n.
infusion of MPTP (1 mg/nostril). Data are expressed as the
mean7S.E.M. of the immobility time (A) and climbing time
(B) in the forced-swimming test [control/control (n¼9);
control/MPTP (n¼11); atorvastatin/control (n¼7); and
atorvastatin/MPTP (n¼8)]. nP≤0.05 compared to the control/
control group. #P≤0.05 compared to the control/MPTP group
(two-way ANOVA followed by Newman–Keuls test).
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Fig. 5 – Effects of the pretreatment (during 7 consecutive
days) with saline or atorvastatin (10 mg/kg, p.o.) on
anhedonic behavior of rats evaluated in the sucrose
consumption test from 14 to 16 days after i.n. infusion of
MPTP (1 mg/nostril). Data are expressed as the mean7S.E.
M. of liquid consumption (g) during the 48-h sucrose and
water intake and during the 24-h training phase [control/
control (n¼6); control/MPTP (n¼7); atorvastatin/control
(n¼7); and atorvastatin/MPTP (n¼8)]. #P≤0.05 compared to
the water intake of the respective group (Student’s t-test).
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The effects of the pretreatment with saline or atorvastatin
(10 mg/kg, p.o.) on the depressive-like behavior of rats
evaluated in the forced swimming test at 14 days after i.
n. administration of MPTP (1 mg/nostril) are summarized in
Fig. 4. Two-way ANOVA revealed signiﬁcant effects for the
pretreatment [F(1,31)¼17.81, P¼0.00022], treatment [F
(1,31)¼4.70, P¼0.025] and their interaction [F(1,31)¼22.45,
P¼0.00013] in the immobility time. Subsequent post-hoc
comparisons indicated that MPTP-treated rats presented
higher immobility time in comparison to control group
(P¼0.00021), suggesting a depressive-like proﬁle. The
pretreatment with atorvastatin prevented the depressive-
like behavior of MPTP-treated rats as indicated by a sig-
niﬁcant reduction in the immobility time (P¼0.00024)
(Fig. 4A). On the other hand, two-way ANOVA revealed no
signiﬁcant effects for the pretreatment [F(1,31)¼0.27,
P¼0.60] and treatment [F(1,31)¼0.007, P¼0.93] factors in
climbing time (Fig. 4B), used as a parameter of motor
activity scored directly in the forced swimming test
(Vieira et al., 2008).2.4. Sucrose consumption
During the initial training phase, in which the rats were
habituated to drink from two bottles (both ﬁlled with water),
no signiﬁcant difference was observed in water intake
between the experimental groups (Fig. 5). Moreover, two-
way ANOVA revealed no signiﬁcant effects for the
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Fig. 6 – Effects of the pretreatment (during 7 consecutive
days) with saline or atorvastatin (10 mg/kg, p.o.) on
locomotor activity of rats evaluated in the activity chamber
21 days after i.n. infusion of MPTP (1 mg/nostril). Each value
represents the mean7S.E.M. of crossings during 30 min
[control/control (n¼9); control/MPTP (n¼11); atorvastatin/
control (n¼7); and atorvastatin/MPTP (n¼8)]. nP≤0.05
compared to the control/control group. #P≤0.05 compared to
the control/MPTP group (two-way ANOVA followed by
Newman–Keuls test).
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Fig. 7 – Effects of the pretreatment (during 7 consecutive
days) with saline or atorvastatin (10 mg/kg, p.o.) on
cognitive performance of rats evaluated in the spatial
reference memory version of the water maze from 18 to 21
days after i.n. infusion of MPTP (1 mg/nostril). Values are
shown as mean7S.E.M. latency to escape to a submersed
platform during four training days, with four consecutive
trials per day [control/control (n¼6); control/MPTP (n¼7);
atorvastatin/control (n¼7); and atorvastatin/MPTP (n¼8)].
b r a i n r e s e a r c h 1 5 1 3 ( 2 0 1 3 ) 1 0 3 – 1 1 6 107pretreatment [F(1,24)¼0.18, P¼0.67] and treatment [F(1,24)¼
0.46, P¼0.50] factors in the mean 48-h intake of sucrose
solution at 14 days after i.n. MPTP administration. Finally,
all groups consumed signiﬁcantly more sucrose solution than
water (P≤0.05, unpaired Student's t-test) and no difference in
total water intake during this time was observed (Fig. 5).2.5. Activity chamber
The effects of the pretreatment with atorvastatin (10 mg/kg,
p.o.) on locomotor activity of rats evaluated in the activity
chamber (for 30 min) at 21 days after i.n. MPTP administra-
tion are illustrated in Fig. 6. Two-way ANOVA revealed
signiﬁcant effects for the pretreatment [F(1,31)¼3.39,
P¼0.046], treatment [F(1,31)¼17.21, P¼0.00024] and their
interaction [F(1,31)¼24.69, P¼0.00013] in the number of cross-
ings in the activity chamber. Subsequent Newman–Keuls test
indicated that MPTP-treated rats displayed reduced locomo-
tor activity in comparison to the control group (P¼0.006).
More importantly, the pretreatment with atorvastatin was
able to prevent these long-lasting motor impairments,
increasing signiﬁcantly the number of crossings of MPTP-
infused rats (P¼0.042) (Fig. 6).2.6. Water maze
The data presented in Fig. 7 show that rats treated intrana-
sally with MPTP did not differ from their controls [F(1,24)¼
0.24, P¼0.82] in the escape latency for ﬁnding the platform in
the training sessions when submitted to the spatial reference
memory version of the water maze. The animals from all
experimental groups were able to learn the task, since their
mean escape latency improved throughout the training days.
Moreover, two-way ANOVA indicated that the swimming
speed was not signiﬁcantly affected by atorvastatin and/or
MPTP administration (data not shown).2.7. Immunohistochemistry for tyrosine hydroxylase in
the substantia nigra
With the purpose of determining the relationship between
the motor impairments observed in the activity chamber at
later periods after i.n. MPTP administration in rats and the
loss dopaminergic cells in the nigrostriatal pathway, evalua-
tion of tyrosine hydroxylase (TH)-positive neurons in the
SNpc was performed 21 days after i.n. administration of
MPTP by immunohistochemistry. Fig. 8A–H shows represen-
tative photomicrographs of TH-positive cells in the ventral
mesencephalon containing SNpc of rats from the four experi-
mental groups. Two-way ANOVA revealed no signiﬁcant
effect for the pretreatment factor [F(1,16)¼0.50, P¼0.49].
However, it revealed signiﬁcant effects for the treatment
[F(1,16)¼15.88, P¼0.0082] and the interaction factor between
pretreatment and treatment [F(1,16)¼6.72, P¼0.023]. Subse-
quent Newman–Keuls test indicated that the i.n. administra-
tion of MPTP induced a pronounced reduction (about 80%)
(P¼0.0015) of the immunolabeling of TH-positive cells in the
SNpc of rats. The repeated treatment with atorvastatin
(10 mg/kg/day, p.o.) was able to attenuate signiﬁcantly this
loss (about 50%) (P¼0.024) of TH-positive neurons in the SNpc
of MPTP-treated rats (Fig. 8).2.8. Measurements of TNF-α, IL-1β, IL10 and NGF-β levels
in striatum and hippocampus
One hypothesis of the cause of degeneration of the nigros-
triatal dopaminergic neurons in PD is due to the increased
levels of cytokines and/or decreased ones of neurotrophins
(Nagatsu et al., 2000). With the purpose of determining
possible alterations in inﬂammatory markers and neurotro-
phins following i.n. MPTP treatment, the levels of TNF-α,
IL-1β, IL10 and NGF-β were measured in striatum and
Fig. 8 – Effects of the pretreatment (during 7 consecutive days) with atorvastatin (10 mg/kg, p.o.) on tyrosine hydroxylase
(TH)-positive cells in the substantia nigra pars compacta (SNpc) of rats evaluated through immunohistochemistry at 21 days
after i.n. infusion of MPTP (1 mg/nostril). Representative images of TH immunostaining in the ventral mesencephalon
containing SNpc of rats treated with contro7control (A,B), control7MPTP (C,D), atorvastatin7control (E,F) or
atorvastatin7MPTP (G,H). Scale bar (A,C,E,G¼100 μm and B,D,F,H¼25 μm). Each value represents the mean7S.E.M. of 5
animals in each group. nP≤0.05 compared to the control/control group; #P≤0.05 compared to the control/MPTP group
(two-way ANOVA followed by Newman–Keuls test).
b r a i n r e s e a r c h 1 5 1 3 ( 2 0 1 3 ) 1 0 3 – 1 1 6108hippocampus of rats at 21 days after i.n. MPTP infusion. As
illustrated in Fig. 9, two-way ANOVA revealed no signiﬁcant
effects for the pretreatment and treatment factors in the
levels of the cytokines TNF-α, IL-1β and IL10 in striatum and
hippocampus. Interestingly, the pretretment with atorvasta-
tin (10 mg/kg, p.o.) induced a long-lasting increase in NGF-β
levels in both striatum [F(1,20)¼11.03, P¼0.0045] (Fig. 9D) and
hippocampus [F(1,20)¼18.40, P¼0.0011] (Fig. 9H) of rats.3. Discussion
PD is associated with a number of non-motor symptoms
including hyposmia, sleep disturbances, gastrointestinal dys-
function, autonomic dysfunction, anxiety, depression, and
cognitive decline, which can precede the classical motor
features of PD by years and contribute substantially for the
loss of quality of life in PD patients (Chaudhuri and Odin,
2010). As recently highlighted by Taylor et al. (2010), animal
models of PD should also present non-motor behavioral
features of this disease. This requires that typically beha-
vioral test batteries (mainly based on motor tests) be
expanded. In this context, some preclinical studies have
begun to demonstrate that through the use of low doses
and/or speciﬁc routes of administration (e.g., intranigral,
intrastriatal, intranasal), some toxins widely used to induce
experimental parkinsonism such as MPTP and 6-OHDA
induces a moderate loss of the nigral dopamine neurons
resulting in sensorial, emotional and memory deﬁcits with no
major motor impairments (Da Cunha et al., 2002; Miyoshiet al., 2002; Prediger et al., 2006, 2011; Tadaiesky et al., 2008;
Santiago et al., 2010).
The present data indicated that signiﬁcant motor deﬁcits
were only observed at 21 days after i.n. MPTP administration
in rats. This late decrease in locomotor activity of MPTP-
treated rats was accompanied by a marked reduction (about
80%) of TH-positive neurons in the SNpc. These results
corroborate previous ﬁndings using the i.n. MPTP model
where a moderate reduction in locomotor activity of MPTP-
treated rats in the open-ﬁeld and activity chambers was only
observed at 21 and 32 days, respectively, after i.n. MPTP
infusion (Prediger et al., 2006; Moreira et al., 2010). Of high
importance, the administration of atorvastatin demonstrated
its neuroprotective properties as previously described in
several models of neuronal damage (Piermartiri et al., 2009;
2010), preventing the locomotor impairments and the
decrease of the TH immunoreactivity in the SNpc induced
by i.n. infusion of MPTP in rats.
Over the last years, there is an increasing number of
studies addressing the effects of statins in PD. Epidemiologic
studies have generated mixed results regarding statin use
and PD risk. Signiﬁcant protective effects of statins were
observed in two retrospective case-control studies (Huang
et al., 2007; Wahner et al., 2008). However, recall and selection
biases cannot be ruled out in these studies. Moreover, a
signiﬁcantly inverse association between use of statins and
PD risk was observed in some (Wolozin et al., 2007; Hippisley-
Cox and Coupland, 2010) but not all (Becker et al., 2008; Ritz
et al., 2010) prospective studies using registry data. Recently,
Gao et al. (2012) published a large prospective study including
38,192 men and 90,874 women participating in two ongoing
Fig. 9 – Effects of the pretreatment (during 7 consecutive days) with atorvastatin (10 mg/kg, p.o.) on TNF-α, IL-1β, IL10 and
NGF-β levels in the striatum (A–D) and hippocampus (E–H) of rats 21 days after i.n. infusion of MPTP (1 mg/nostril). Data are
expressed as means7S.E.M. of pmol/mg protein of 6 animals in each group. #P≤0.05 compared to the pretreatment with
control (two-way ANOVA followed by the Newman–Keuls test).
b r a i n r e s e a r c h 1 5 1 3 ( 2 0 1 3 ) 1 0 3 – 1 1 6 109US cohorts. The authors described that regular use of statins
was associated with a reduction in PD risk in participants
younger than 60 years at baseline but not among those who
were older.
The observed association between regular use of statins
and lower PD risk corroborates recent ﬁndings demonstrating
that statins slowed down dopaminergic degenerationobserved in diverse experimental models of PD (Selley, 2005;
Hernández-Romero et al., 2008; Ghosh et al., 2009; Yan et al.,
2011; Kumar et al., 2012). For instance, in vivo and in vitro
studies suggest that statins could reduce α-synuclein accu-
mulation and oxidative stress, suppress cyclooxygenase 2
expression, reduce the release of TNF-α and nuclear factor κB
activation, activate peroxisome proliferator-activated
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the brain (Becker and Meier, 2009; Wood et al., 2010; Wang
et al., 2011). Taken together, these results suggest that statins
may represent potential disease-modifying agents for PD.
However, no consistent evidence for the effects of such
agents in the non-motor symptoms of PD has to date been
documented.
Since the i.n. administration of MPTP does not cause, at
least at initial periods, gross motor alterations that would
preclude assessment of cognitive and emotional functions,
we also investigated whether such behaviors are affected in
these animals. The social recognition memory is a particular
model of olfactory memory mediated by olfactory cues
(Sawyer et al., 1984) and may involve a non-procedural form
of a short-term working memory based upon the olfactory
discriminative ability of rats. It is important to emphasize
that dopamine seems to be necessary for social recognition
memory in rodents, since treatments with dopamine recep-
tors antagonists (Prediger et al., 2004, 2005) or drugs that
reduce dopaminergic neurotransmission such as reserpine
(Prediger et al., 2004, 2005) or MPTP (Moreira et al., 2010;
Castro et al., 2012) inhibit short-term olfactory memory.
Corroborating these previous ﬁndings, we observed in the
present study that rats infused intranasally with MPTP (1 mg/
nostril) spent signiﬁcantly more time investigating the juvenile
rat during the second presentation than they did in the ﬁrst
encounter, suggesting an impaired ability to recognize the
juvenile rat after a short time. Of high importance, the present
ﬁndings demonstrate for the ﬁrst time that the treatment with
atorvastatin (10 mg/kg) by oral route during seven consecutive
days was able to prevent the short-term social recognition
memory impairments in MPTP-treated rats. Interestingly,
Wolozin et al. (2007) analyzed data from the decision support
system of the US Veterans Affairs database to evaluate whether
the use of statins is associated with a reduced incidence of
dementia and PD. The authors described that simvastatin is
associated with a strong reduction in the incidence of dementia
and PD, whereas atorvastatin is associated with a modest
reduction in incident dementia and PD. Therefore, from these
limited results it appears that statins might be particularly
useful to improve impaired memory processes in PD.
In addition, spatial memory impairments have been
observed in rats stereotaxically injected with MPTP into the
SNpc (Wang et al., 2009, 2010; Hsieh et al., 2012). Therefore,
we investigated putative spatial memory dysfunction in rats
from 18 to 21 days after i.n. MPTP administration by using
Morris water maze task. Rats infused intranasally with MPTP
did not differ from their controls in the escape latency for
ﬁnding the platform and all experimental groups were able to
learn the task.
These ﬁndings are in accordance with previous studies
from our group demonstrating that rats treated intranasally
with MPTP performed normally in the long-term retention
session (24 h after training) of the inhibitory avoidance task
(Castro et al., 2012) and in the spatial reference memory
version of the water maze (Prediger et al., 2006). In contrast,
MPTP-infused rats displayed a poor performance in the short-
term retention session (1.5 h after training) of the inhibitory
avoidance task (Castro et al., 2012), in the working memory
version of the water maze (Prediger et al., 2006) and in thesocial recognition task (Moreira et al., 2010; Castro et al.,
2012). These ﬁndings are consistent with the view of human
studies suggesting that PD patients present early deﬁcits in
working memory and short-term memory tasks mainly
dependent on the frontostriatal circuitry (for review see
Zgaljardic et al., 2003) with long-term spatial (declarative)
memories mostly spared (Dubois and Pillon, 1997; Bosboom
et al., 2004).
Beyond the cognitive symptoms, depressive disorders
commonly occur in PD affecting approximately 40% of the
patients during the early stages of the disease (Tolosa et al.,
2007). Recent preclinical studies have provided strong evi-
dence that classical neurotoxin models of PD (such as
6-OHDA and MPTP) are able to induce depressive-like behaviors
in rodents with no major motor impairments (Tadaiesky et al.,
2008; Moreira et al., 2010; Santiago et al., 2010). In accordance
with previous ﬁndings described by Moreira et al. (2010), in the
present study we observed that the i.n. infusion of MPTP (1mg/
nostril) caused a depressive-like behavior in rats, reﬂected by an
increased immobility time in the forced swimming test. This
depressive-like behavior might be correlated with dopamine
changes at striatal level (Tadaiesky et al., 2008; Castro et al.,
2012). In addition, anhedonia is a classical feature of depression
and involves decreased libido and a lack of desire for other
pleasurable experiences. Sucrose consumption is frequently
used as a measure of anhedonia in rodents, and Tadaiesky
et al. (2008) described that intrastriatal administration of 6-
OHDA promoted an early decrease in sucrose consumption
measured 1 week after 6-OHDA treatment. However, in the
current study we failed to observe similar anhedonic behavior in
rats infused intranasally with MPTP. Therefore, the toxin, the
low dose of MPTP and/or the route of administration utilized in
the current study may explain, in part, the discrepancy with the
previous ﬁndings reported by Tadaiesky et al. (2008).
Of high interest, the treatment with atorvastatin signiﬁ-
cantly prevented the behavioral despair induced by i.n. MPTP,
inferred from the fact that atorvastatin-treated animals
showed a similar level of immobility time as the control
group. These results represent the ﬁrst evidence that ator-
vastatin may prevent depressive-like behavior in an experi-
mental model of PD. Interestingly, clinical data indicates that
statins therapy is linked to a reduction in the incidence of
depression and anxiety (Young-Xu et al., 2003), although the
mechanisms of action are not established. Moreover, we
recently demonstrated that atorvastatin treatment may dis-
play antidepressant-like effects in mice (Ludka et al., 2012).
However, further research is needed to clarify the exact
molecular mechanisms involved in the antidepressive-like
effect induced by atorvastatin in MPTP-treated rats.
There is increasing evidence that inﬂammation plays a key
role in the pathophysiology of PD (for review see Hirsch and
Hunot, 2009). Previous studies using animal models of PD
reported that statins attenuate the production of inﬂamatory
markers in activated microglia thereby protecting dopaminergic
neurons from inﬂammatory damage (Selley, 2005; Yan et al.,
2011; Kumar et al., 2012). However, contrasting with previous
ﬁndings showing microglial activation and accumulation of
inﬂammatory mediators in the substantia nigra, striatum and
hippocampus of rodents after MPTP injection (Liberatore et al.,
1999; Sriram et al., 2002; Selley, 2005; Wang et al., 2009, 2010),
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tions in concentrations of the cytokines TNF-α, IL-1β and IL-10
in striatum and hippocampus of rats. In this regard, it is
important to emphasize that the neurotoxicity induced by
MPTP in laboratory animals seems to be dependent on many
variables, such as species, strain, gender, age and/or the
schedule of treatment utilized (Sedelis et al., 2000; Przedborski
et al., 2001). Bezard et al. (1997) proposed that different sche-
dules (e.g., dose, duration and route of administration) of MPTP
might induce different mechanisms of neuronal death.
Interestingly, we observed that the current treatment with
atorvastatin (10 mg/kg/day, p.o.) during 7 consecutive days
increase signiﬁcantly the levels of NGF in striatum and
hippocampus of rats. NGF is a neurotrophic factor and the
exogenous application of NGF has been shown to increase the
level of antioxidant enzymes, heme oxygenase-1 and prevent
apoptosis by inducing antiapoptotic gene signaling pathways
following exposure to 6-OHDA and MPTP (Shimoke and
Chiba, 2001; Salinas et al., 2003). It has also been shown that
NGF level is decreased in PD patients and experimental
parkinsonian rats (Lorigados Pedre et al., 2002). Taking
together the above reports, we can speculate that the neuro-
protective effects of atorvastatin against the behavioral and
neurochemical alterations induced by i.n. MPTP administra-
tion may result, at least in part, from the increase in NGF
levels. However, the sequence of events leading to the
protective effects of atorvastatin against cell damage remains
to be elucidated.
In conclusion, the present study provides the ﬁrst pre-
clinical data indicating that repeated systemic treatment
with atorvastatin prevents short-term memory and
depressive-like behavior as well as dopaminergic cell loss in
the SNpc of rats submitted to an experimental model of PD.
These results provide new insights into experimental models
of PD, indicating that atorvastatin may represent a new
therapeutic tool for the management of motor and non-
motor symptoms of PD, together with its neuroprotective
potential.4. Experimental procedure
4.1. Animals
The subjects were adult male Wistar rats (4 months old,
300–350 g) and juvenile male Wistar rats (25–30 days old)
provided by the animal facility of the Universidade Federal de
Santa Catarina (UFSC, Florianópolis, Brazil). Juvenile rats were
kept in groups of ten per cage and served as social stimuli for
the adult rats in the social recognition task. Animals were
maintained in a 12-h light–dark cycle (lights on at 6:00 a.m.)
at constant room temperature (2272 1C) and humidity
(6075%) and were housed in groups of ﬁve animals per cage
(493416 cm) with free access to food and water. The
animals were allowed to adapt to the laboratory conditions
for at least 1 week before the behavioral assessment and all
tests were carried out between 9:00 and 14:00 h. All proce-
dures used in the present study complied with the guidelines
on animal care of the UFSC Ethics Committee on the Use of
Animals which follows the “Principles of laboratory animalcare”. All experimental protocols were designed with the goal
of keeping the number of animals used to a minimum, as
well as their suffering. These protocols were conducted in
accordance with national and international legislation
(guidelines of Brazilian Council of Animal Experimentation –
CONCEA – and of U.S. Public Health Service's Policy on
Human Care and Use of Laboratory Animals—PHS Policy),
and with the approval of the Ethics Committee for Animal
Research of the Universidade Federal de Santa Catarina
(Process 23080.037860/2010-31).
4.2. Drugs and treatment
The animals were allocated to the following groups: (i) control
+control (n¼15), (ii) control+MPTP (n¼18), (iii) atorvastatin
+control (n¼14) or (iv) atorvastatin+MPTP (n¼16). Atorvasta-
tin was extracted from commercially available capsules
(Lipitors, Pﬁzer, São Paulo, Brazil). Capsules of LIPITORs
(atorvastatin calcium) containing 40 mg atorvastatin were
weighed and ﬁnely powdered and then transferred into a
10-ml calibrated ﬂask, dissolved in 4 ml sterile saline solution
(0.9% NaCl), swirled and sonicated for 5 min, completed to
volume with saline and shaken well for 15 min immediately
before administration. The effect of the repeated systemic
administration of atorvastatin on MPTP-induced behavioral
deﬁcits and dopaminergic cell death was investigated by
administrating atorvastatin (10 mg/kg/day) or its vehicle
(sterile saline solution—0.9% NaCl) during 7 consecutive days
by oral route (p.o.) (Fig. 1). The current atorvastatin dose and
schedule for administration were chosen based on previous
studies (Piermartiri et al., 2009,2010) and in pilot experiments
(data not shown). Six hours before the 4th administration of
atorvastatin, the animals were infused intranasally with a
single bilateral dose of MPTP (1 mg/nostril) or saline (control).
MPTP HCl (Sigma Chemical Co., USA) was administered by
i.n. route according to the procedure described by Prediger
et al. (2006). Brieﬂy, rats were lightly anaesthetized with
isoﬂurane 0.96% (0.75 CAM; Abbot Laboratórios do Brasil
Ltda., RJ, Brazil) using a vaporizer system (SurgiVet Inc., WI,
USA) and a 10-mm piece of PE-50 tubing was inserted through
the nostrils. The tubing was connected to a peristaltic pump
set at a ﬂow rate of 12.5 μl/min. The MPTP HCl was dissolved
in 0.9% NaCl (saline) at a concentration of 20 mg/ml, after
which it was infused for 4 min (1 mg/nostril). The control
solution consisted of saline. Animals were given a 1-min
interval to regain normal respiratory function and then this
procedure was repeated with infusions administered through
the contralateral nostrils. MPTP was handled in accordance
with the guidelines (Przedborski et al., 2001).
4.3. Behavioral and biochemical analysis
During a period of 7–21 days after the i.n. administration of
MPTP, the animals were submitted to a battery of behavioral
and biochemistry analysis (Fig. 1) that included the social
recognition, open-ﬁeld, forced swimming, sucrose consump-
tion, activity chamber and water maze tasks, and the quanti-
ﬁcation of IL-1β, TNF-α, NGF-β and IL10 levels in striatum and
hippocampus and immunohistochemistry for TH in the SNpc.
The tests were conducted in two independent cohorts rats.
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forced swimming and activity chamber and the animals were
killed 21 days after i.n. infusion of MPTP or vehicle for the
measurement of TH immunohistochemistry in the SNpc.
The second group was tested in the sucrose consumption
and water maze and the animals were killed 21 days after i.n.
infusion of MPTP or vehicle for quantiﬁcation of cytokines
and NGF-β using speciﬁc enzyme-linked immunosorbent
assay (ELISA).
The time point for the performance of each behavioral
task was chosen based on previous studies using the i.n.
MPTP model (Prediger et al., 2006, 2011; Moreira et al., 2010;
Castro et al., 2012). All tests were scored by the same rater in
an observation room where the rats had been habituated for
at least 1 h before the beginning of the tests. Behavior was
monitored through a video camera positioned above the
apparatuses and the images were later analyzed with the
ANY Maze video tracking (Stoelting Co., Wood Dale, IL, USA)
by an experienced experimenter who was unaware of the
experimental group of the animals tested.
4.3.1. Social recognition
Short-term social memory was assessed 7 days after i.n.
MPTP administration with the social recognition task
described by Dantzer et al. (1987) and previously evaluated
in our laboratory (Prediger et al., 2004; Castro et al., 2012).
All juveniles were isolated in individual cages for 20 min prior
to the beginning of the experiment. The social recognition
task consisted of two successive presentations (5 min each),
separated by a short period of time, where the juvenile rat
was placed in the home cage of the adult rat and the time
spent by the adult in investigating the juvenile (nosing,
snifﬁng, grooming, or pawing) was recorded. At the end of
the ﬁrst presentation, the juvenile was removed and kept in
an individual cage during the delay period and re-exposed to
the same adult rat after 30 min. In this paradigm, if the delay
period is less than 40 min, the adult rodents display recogni-
tion of this juvenile, as indicated by a signiﬁcant reduction in
the social investigation time during the second presentation
(Dantzer et al., 1987; Prediger et al., 2004).
Time spent in social investigation by the adult rat was
measured and then expressed for each animal as the ratio of
the second exposure to the ﬁrst exposure (Ratio of Investiga-
tion Duration (RID)). A reduction in RID reﬂects a decrease in
investigation behavior during the second encounter, demon-
strating the recognition ability of the adult rat. This transfor-
mation was chosen in order to minimize day-to-day
variations on the baseline of performance and to equalize
variances among different groups (Dantzer et al., 1987;
Prediger et al., 2004).
4.3.2. Open-ﬁeld
To rule out early effects of tested drugs on locomotor activity,
the animals were placed for 5 min in an open-ﬁeld arena at 14
days after i.n. MPTP administration. The apparatus, made of
wood covered with impermeable Formica, had a gray ﬂoor of
100100 cm and transparent walls, 40 cm high. Each rat was
placed in the center of the apparatus and the total distance
traveled (m) and the average speed (m/s) were registered for
5 min using the ANY-mazes video tracking system (StoeltingCo., Wood Dale IL, USA) (Castro et al., 2012). The apparatus
was cleaned with 10% ethanol between animals.
4.3.3. Forced swimming
The depressive-like effect was assessed 14 days after i.n.
MPTP administration with the forced-swimming test pre-
viously described by Porsolt et al. (1977). Rats were placed
in individual glass cylinders (40 cm in height and 17 cm in
diameter) containing water (water depth was 30 cm; 2571 1C).
Two swimming sessions were conducted (an initial 15-min
training followed 24 h later by a 5-min test). The water was
changed and the cylinder rinsed with clean water after each
rat. Following the training and the test sessions, the animals
were dried in a heated enclosure. During the 5 min swimming
test session, the following behavioral responses were
recorded by a trained observer: the immobility time (i.e. the
time spent ﬂoating in the water without struggling, making
only those movements necessary to keep the head above the
water) and climbing behavior, which is deﬁned as upward
directed movements of the forepaw along the cylinder walls.
Decrease in immobility time is indicative of a reduction in
depression-related behaviors, while time of climbing was
used as a predictor of altered motor activity scored directly
in the forced swimming test (Vieira et al., 2008).
4.3.4. Sucrose consumption
Anhedonia is a classical feature of depression and involves
decreased libido and a lack of desire for other pleasurable
experiences. Sucrose consumption is frequently used as a
measure of anhedonia in rodents, including in experimental
models of PD (Tadaiesky et al., 2008). At 14 days after i.n.
MPTP administration, animals were transferred into single
housing cages with free access to food. Each rat was provided
with two water bottles on the extreme sides of the cage
during the 24-h training phase to adapt the rats to drinking
from two bottles. After training, one bottle was randomly
switched to contain 0.8% sucrose solution, as described
previously (Slattery et al., 2007), and 24 h later, the bottles
were reversed to avoid perseveration effects. The use of a
48-h testing period allowed us to preclude any effects of
neophobia, artifactual bias toward any particular side and
perseveration effects. The consumption of water and sucrose
solution was estimated simultaneously in groups by weigh-
ing the bottles.
4.3.5. Activity chamber
In order to assess possible long-lasting effects of MPTP on
locomotor activity, the animals were tested 21 days after i.n.
MPTP administration in activity chambers during a period of
30 min (Moreira et al., 2010). The activity chamber consists of
a wooden cage (70 cm28 cm25 cm) with steel grid ﬂoor
and equipped with automatic movement detection using
three pairs of infrared beans positioned 2 cm above the ﬂoor
and evenly placed in the apparatus. The locomotion was
automatically measured by a digital counter that recorded
photocell beam interruptions.
4.3.6. Water maze
To evaluate the existence of long-lasting spatial memory
deﬁcits after the i.n. administration of MPTP in rats, the
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treatment to a spatial reference memory version of the water
maze using a protocol described previously (Morris et al.,
1982). Tests were performed in a circular swimming pool
made of black painted ﬁberglass, 1.7 m inside diameter, 0.8 m
high, which was ﬁlled to a depth of 0.6 m with water
maintained at 25 1C. The target platform (1010 cm) was
made of transparent Plexiglas and was submerged 1–1.5 cm
beneath the surface of the water. Starting points for the
animals were marked on the outside of the pool as north (N),
south (S), east (E) and west (W). Four distant visual cues
(5555 cm) were placed on the walls of the water maze
room. They were all positioned with the lower edge 30 cm
above the upper edge of the water tank, and in the standard
setting the position of each symbol marked the midpoint of
the perimeter of a quadrant (circle¼NE quadrant, square¼SE
quadrant, cross¼SW quadrant, and diamond¼NW quad-
rant). The protocol consisted of 4 training days, four con-
secutive trials per day, during which the animals were left in
the tank facing the wall, then being allowed to swim freely to
the submerged platform placed in the center of southwest
quadrant of the tank. If the animal did not ﬁnd the platform
during a period of 60 s, it was gently guided to it. The animal
was allowed to remain on the platform for 10 s after escaping
to it and was then removed from the tank for 20 s before
being placed at the next starting point in the tank. The
apparatus was located in a room with indirect incandescent
illumination. A monitor and a video-recording system were
installed in an adjacent room. The experiments were video-
taped and the scores for latency of escape from the starting
point to the platform and swimming speed were later
measured using the ANY-mazes video tracking system
(Stoelting Co., Wood Dale IL, USA).
4.3.7. Immunohistochemistry for tyrosine hydroxylase (TH)
For the investigation of possible neuroprotective effects of
atorvastatin against the loss of dopaminergic neurons
induced by i.n. MPTP administration, ﬁve animals of each
group were intracardiacally perfused with physiological
saline (NaCl 0.9%) followed by a solution of 4% paraformal-
dehyde in 0.1 M phosphate buffer, pH 7.4, 21 days after MPTP
treatment. Brains were removed and post-ﬁxed for 4 h in the
same solution and cryoprotected by immersion in 30%
sucrose in 0.1 M PBS for 48 h. For each brain, serial coronal
sections (50 μm) were obtained using a cryostat (Leica, CM
1850 UV) at −20 1C and collected in PBS. For immunohisto-
chemistry, the free-ﬂoating sections were pretreated with
10% methanol diluted in 3% hydrogen peroxidase for 30 min,
carefully washed and blocked with 2% albumin in 0.1 M
phosphate saline buffer pH 7.4, containing 0.3% Triton X-
100 (PBS-Tx, Sigma) for 30 min and incubated with anti-TH
monoclonal antibody (1:1000, MAB318, Millipore/Chemicon
International Technology, USA) for 48 h at 4 1C as described
previously (Ferraz et al., 2003). After washing several times
with PBS-Tx, tissue sections were incubated with a biotiny-
lated secondary antibody (Dako, Carpinteria, CA) diluted 1:200
in PBS-Tx at room temperature for 2 h. The immunohisto-
chemical reaction was developed by incubating the sections
in a medium containing 0.06% 3,3-diaminobenzidine (DAB,
Sigma) dissolved in PBS for 10 min, and then in the samesolution containing 1 μM of 3% H2O2 per ml of DAB medium
for 10 min. The sections were rinsed with PBS, dehydrated
with ethanol, cleared with xylene, and covered with Per-
mount and coverslips. Control sections were prepared by
omitting the primary antibody and replacing it with PBS. All
brains were ﬁxed and postﬁxed for the same time in identical
solutions and rigorously processed at the same time, and
sections were incubated in an identical medium for the same
period of time. This precaution was taken to avoid over
reaction, differences in chromogen reaction, saturation of
optical density, and changes in background levels (Ferraz
et al., 2003). Coronal sections of the SNpc were selected for
this immunohistochemical study. These areas were identiﬁed
according to the atlas of Paxinos and Watson (2005) and the
readings were made between the coordinates interaural
4.2 mm, bregma −4.8 mm and interaural −2.7 mm, bregma
−6.3 mm. TH-positive neurons in SNpc were determined on
visual inspection with Sight DS-5 M-L1 digital camera (Nikon,
Melville, NY, USA) connected to an Eclipse 50i light micro-
scope (Nikon) using a counting grid at a 5x and 40x
magniﬁcation.4.3.8. Determination of IL-1β, TNF-α, NGF-β and IL10 levels in
rat striatum and hippocampus
Six rats from each group were killed by decapitation 21 days
after i.n. administration of MPTP or vehicle. Brains were
removed immediately and the structures striatum and hip-
pocampus were dissected and homogenized with PBS buffer
containing 0.05% Tween 20, 0.1 mM phenylmethylsulfonyl
ﬂuoride, 0.1 mM benzethonium chloride, 10 mM EDTA and
20 IU aprotinin A. The homogenates were centrifuged at
3000 g for 10 min and the supernatants stored at −80 1C
until assays for the determination of levels of IL-1β, TNF-α,
IL-10 and NGF-β were carried out. The amount of protein in
each sample was measured using the method of Bradford
(1976), using bovine serum albumin as a standard. The levels
of each cytokine and NGF-β were evaluated using enzyme-
linked immunosorbent assay (ELISA) kits according to the
manufacturer's recommendations (R&D systems, Minneapo-
lis, MN, USA) and the results are expressed in pg/mg of
protein in each sample.4.4. Statistical analysis
All values are expressed as means7S.E.M. (n equals the
number of rats included in each analysis). The statistical
analysis was carried out using two-way analysis of variance
(ANOVA) with pretreatment (control vs. atorvastatin) and
treatment (control vs. MPTP) as independent variables. Data
from the water maze task were analyzed using two-way
ANOVA with repeated measure (number of training days).
Following signiﬁcant ANOVAs, multiple post-hoc compari-
sons were performed using the Newman–Keuls test. The
comparisons of water and sucrose intake in each group were
performed using unpaired Student's t-test. The accepted level
of signiﬁcance for the tests was P≤0.05. All tests were
performed using the Statisticas software package (StatSoft
Inc., Tulsa, OK, USA).
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